
Actinium Pharmaceuticals, Inc. — Investor Relations & Filings
Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| CURRENT REPORT | 2026-05-29 | English | |
| 10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer) | 2026-03-30 | English | |
| 8-K/A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer) | 2026-03-26 | English | |
| 8-K - ACTINIUM PHARMACEUTICALS, INC. (0001388320) (Filer) | 2026-02-13 | English | |
| CURRENT REPORT | 2025-11-26 | English | |
| QUARTERLY REPORT | 2025-11-14 | English |
Browse filings by year
20 years- 2026 4 filings
- 2025 18 filings
- 2024 21 filings
- 2023 18 filings
- 2022 21 filings
- 2021 17 filings
- 2020 44 filings
- 2019 29 filings
- 2018 49 filings
- 2017 50 filings
- 2016 38 filings
- 2015 29 filings
- 2014 42 filings
- 2013 68 filings
- 2012 10 filings
- 2011 4 filings
- 2010 5 filings
- 2009 12 filings
- 2008 5 filings
- 2007 9 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 47894542 | CURRENT REPORT | 2026-05-29 | English | ||
| 33092923 | 10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer) | 2026-03-30 | English | ||
| 33052420 | 8-K/A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer) | 2026-03-26 | English | ||
| 32891037 | 8-K - ACTINIUM PHARMACEUTICALS, INC. (0001388320) (Filer) | 2026-02-13 | English | ||
|
2025
11 filings
| |||||
| 12104480 | CURRENT REPORT | 2025-11-26 | English | ||
| 12104479 | QUARTERLY REPORT | 2025-11-14 | English | ||
| 12104482 | ARS | 2025-11-05 | English | ||
| 12104484 | PROXY STATEMENT | 2025-11-05 | English | ||
| 12104488 | Director's Dealing 2025 | 2025-08-20 | English | ||
| 12104487 | QUARTERLY REPORT | 2025-08-08 | English | ||
| 12104491 | Major Shareholding Notification 2025 | 2025-07-29 | English | ||
| 12104505 | Major Shareholding Notification 2025 | 2025-07-17 | English | ||
| 12104504 | QUARTERLY REPORT | 2025-05-09 | English | ||
| 12104507 | CURRENT REPORT | 2025-05-09 | English | ||
| 12104508 | OWNERSHIP DOCUMENT | 2025-04-03 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Avagenesis Corp.
Develops automated technology for isolating and enriching r…
|
VVA | CA | Manufacturing |
|
Avalon GloboCare Corp.
Develops cell-based immunotherapies and provides precision …
|
ALBT | US | Manufacturing |
|
AVECHO BIOTECHNOLOGY LIMITED
Develops human and animal health products using TPM® drug d…
|
AVE | AU | Manufacturing |
|
Avicanna Inc.
Commercial-stage international biopharma focused on evidenc…
|
AVCN | CA | Manufacturing |
|
Avidity Biosciences, Inc.
Develops a class of RNA therapeutics called Antibody Oligon…
|
RNA | US | Manufacturing |
|
Avivagen Inc.
Developed natural health products and feed additives; filed…
|
VIV | CA | Manufacturing |
|
Awakn Life Sciences Corp. (1169082 BC Ltd.)
Clinical-stage biotech developing novel therapeutics, inclu…
|
AWKN | CA | Manufacturing |
|
Axcan Pharma Inc.
Specialty pharmaceutical company focused on prescription th…
|
AXCA | CA | Manufacturing |
|
Axogen, Inc.
Develops and commercializes surgical solutions for peripher…
|
AXGN | US | Manufacturing |
|
Axsome Therapeutics, Inc.
A biopharmaceutical company developing therapies for centra…
|
AXSM | US | Manufacturing |
Actinium Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34570/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34570 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34570 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34570 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34570}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Actinium Pharmaceuticals, Inc. (id: 34570)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.